Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: GlobeNewswire
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior program guidance Company to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1 with a partner Well-capitalized with $911 million in cash as of September 30, 2024, and runway into mid-2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $60.00 price target on the stock.MarketBeat
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $55.00 price target on the stock.MarketBeat
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $38.00.MarketBeat
- Kymera Therapeutics to Participate in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Participate in Upcoming December Investor ConferencesGlobeNewswire
KYMR
Earnings
- 10/31/24 - Beat
KYMR
Sec Filings
- 12/2/24 - Form 4
- 12/2/24 - Form 144
- 11/14/24 - Form SC
- KYMR's page on the SEC website